Compare Bristol-Myers Squibb Co (BMY) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Bristol-Myers Squibb Co trades at $57.41 (market cap $116.30B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.62. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| BMY | VTIP | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $50.75 |
52-Week Low | $42.60 | $49.39 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
VTIP trades at $49.61, down slightly by 0.06% with a bearish technical signal from moving averages. The ETF focuses on short-term inflation-protected securities, offering investors protection against persistent inflation currently running at 3.8%. Recent institutional activity shows mixed positioning with several firms increasing holdings while others trimmed positions. The overall technical picture remains cautious despite neutral oscillator readings.
VTIP provides inflation hedging with potential 3.8% returns in the current environment, though the Fed's reluctance to cut rates in 2026 presents headwinds. The ETF's short-term TIPS focus reduces duration risk but remains sensitive to inflation expectations and monetary policy shifts. Key risks include interest rate volatility and inflation trajectory uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
